Roka Bioscience, which develops highly-automated molecular diagnostic testing systems for the detection of foodborne pathogens, raised $60 million by offering 5 million shares at $12, below the $14-$16 range. At its offer price, Roka now commands a market cap of $217 million and an enterprise value of $158 million. Roka Bioscience will list on the NASDAQ under the symbol ROKA. BofA Merrill Lynch, Leerink Partners, Cowen & Company and Wedbush PacGrow acted as joint bookrunners on the deal.
